Alzheimer’s Drugs Market Key Factors Driving Growth Insights and Forecast Analysis during 2017-2025
Alzheimer’s Drugs Market |
During the forecast period, it is anticipated that the market
for Alzheimer's disease will expand quickly. All mental and memory functions
could be lost in the later stages of the illness. In the world, there are
approximately 55 million people who have dementia, and each year, there are
almost 10 million new cases, according to a report from the World Health
Organization from September 2021. According to the same source, Alzheimer's
disease accounts for 60–70% of all cases of dementia, making it the most prevalent
type. Governments and non-governmental organisations are investing heavily in
the development of diagnostics and treatments for the condition, which could
spur Alzheimer’s
Drugs Market growth, as a result of the rising prevalence of Alzheimer's disease in
the world.
According To Coherent
Market Insights, The Global Alzheimer’s Drugs Market Was Valued At US$ 7
Billion In 2016 And Is Expected To Witness A CAGR Of 9.5% Over The Forecast
Period (2017 - 2025).
The brain shrinks (atrophy) and brain cells degenerate in
Alzheimer's disease, a neurological condition. Dementia, which is characterised
by a progressive loss of cognitive, behavioral, and social abilities that
reduces a person's ability to function independently, is most frequently caused
by Alzheimer's disease. Medicines may momentarily alter or slow the progression
of symptoms. For a short while, these treatments may be able to maintain
function and independence in Alzheimer's disease patients. Numerous programmes
and services are available for Alzheimer's patients and the people who care for
them.
The global market for visual impairment is expanding mostly
due to the increased prevalence of chronic disorders like dementia. The
increasing cost of healthcare, which aids in enhancing its infrastructure, is a
crucial element influencing the growth rate of the Alzheimer's disease market.
The Alzheimer’s Drugs Market will also grow as awareness-raising efforts by public and
private groups continue to rise. The market for drugs to treat and cure
Alzheimer's disease will also grow as a result of rising medication development
and high disposable income. Along with this, the ageing population is growing,
and people's lifestyles are changing, which will accelerate Alzheimer’s Drugs
Market growth.
Major Companies
involved are- F.
Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical
Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline
plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company
(US), Merck & Co., Inc. (US), Allergan (Ireland), Bristol-Myers Squibb
Company (U.S.), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd.
(Japan), Merz Pharma (Germany), AstraZeneca (UK), Amgen Inc. (US), AbbVie Inc.
(US), Biogen (US), Siemens Healthcare GmbH (Germany)
Comments
Post a Comment